Results from the trial were presented last week at the Heart Rhythm Society’s annual scientific sessions in Boston, the Fridley, Minn.-based company said.
The AdaptivCRT algorithm is designed to personalize cardiac resynchronization therapy and adjusts how implanted CRT devices pace the heart according to evaluations of the patient’s heart rhythm, Medtronic said.
In the AdaptResponse prospective registry study, researchers explored the use of the AdaptivCRT Algorithm across 1,835 patients, and found that use of the algorithm was associated with a 31% relative reduction in all-cause mortality compared to standard CRT devices.
“With AdaptivCRT, we are treating heart failure comprehensively, with technology designed to address the individual needs of each patient. This analysis shows yet another benefit of AdaptivCRT, and we look forward to results from the randomized, superiority AdaptResponse trial in the coming years,” Medtronic cardiac resynchronization therapy biz GM Dr. Kweli Thompson said in a press release.
Medtronic said that prior studies of the algorithm have shown that it can also reduce atrial fibrillation, with data indicating a 46% reduction in episodes of AS lasting more than 48 hours compared to traditional CRT.
“Heart failure patients typically have several other medical conditions and are at risk for frequent hospitalizations and even death. The AdaptivCRT algorithm is not only linked to improved patient survival, but it also has previously been shown to reduce the risk of atrial fibrillation and hospital readmissions,” Dr. Jagmeet Singh of the Massachusetts General Hospital said in a press release.
Last week, Medtronic released one-year results from the post-approval registry study of its Micra leadless transcatheter pacing system, touting a high implant success rate and a low complication rate.